NONOF Company Profile and Key Details

Q: Who are the executives of NONOF?

Ms. Camilla SylvestExecutive Vice President of Commercial Strategy & Corporation Affairs and Member of the Management BoardMr. Maziar Mike DoustdarExecutive Vice President of International Operations & Member of the Management BoardMr. Henrik Ehlers WulffExecutive Vice President of Product Supply, Quality & IT and Member of the Management BoardDr. Marcus Schindler Ph.D.EVice President of Research & Early Devel., Chief Scientific Officer & Member of the Management BoardMr. Douglas J. LangaExecutive Vice President of North America Operations & Member of Management BoardMr. Karsten Munk KnudsenExecutive Vice President, Chief Financial Officer & Member of the Management BoardMr. Ludovic HelfgottExecutive Vice President, Head of Rare Disease & Member of Management BoardMr. Lars Fruergaard JorgensenPres, Chief Executive Officer & Member of Management BoardDr. Martin Holst LangeExecutive Vice President of Devel. & Member of the Management BoardMs. Tania SabroeExecutive Vice President of Global People & Organisation and Member of Management Board

PNK : NONOF

Novo Nordisk A/S

$144.95

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Novo Nordisk A/S (NONOF) stock declined over -0.73%, trading at $44.14 on OTC, down from the previous close of $44.47. The stock opened at $44.00, fluctuating between $43.97 and $44.74 in the recent session.

Stock Snapshot

44.4688

Prev. Close

196.02B

Market Cap

43.9725

Day Low

12.2

P/E Ratio

3.617

EPS (TTM)

15.68

Cash Flow per Share

Open

4.44B

Number of Shares

44.735

Day High

93.02%

Free Float in %

23.87

Book Value

241

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 10, 2026	44.56	45.39	42.98	44.14	10.98K
Sep 09, 2026	45.76	45.76	43.51	44.47	3.46K
Sep 08, 2026	43.15	46.30	43.15	45.44	10.57K
Sep 04, 2026	43.88	47.00	43.88	46.31	1.84K
Sep 03, 2026	47.25	47.50	47.00	47.00	7.4K
Sep 02, 2026	46.50	47.55	45.02	46.85	11.55K
Sep 01, 2026	45.01	46.59	44.85	45.35	9.29K
Aug 31, 2026	42.78	45.93	42.78	45.25	32.66K
Aug 28, 2026	43.90	46.31	43.90	45.02	6.48K
Aug 27, 2026	46.25	46.70	44.00	46.16	286.69K
Aug 26, 2026	48.00	48.10	46.90	47.20	253.28K
Aug 25, 2026	48.00	48.25	47.90	48.25	304.2K
Aug 24, 2026	46.90	47.10	46.60	46.85	82.82K
Aug 21, 2026	46.74	47.46	46.38	46.81	655.22K
Aug 20, 2026	47.69	47.69	45.51	46.33	86.99K
Aug 19, 2026	47.30	47.30	44.97	45.40	4.28K
Aug 18, 2026	44.78	44.78	44.78	44.78	47.64K
Aug 17, 2026	45.98	45.98	44.50	45.11	3.63K
Aug 14, 2026	47.00	47.19	43.67	45.14	4.55K
Aug 13, 2026	45.45	47.00	44.95	45.79	3.83K

Contact Details

Bagsvaerd, CR 2880

Denmark

https://www.novonordisk.com 454 444 8888

About Company

Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health conditions. Meanwhile, the Biopharmaceuticals division is focused on specialized treatments for hemophilia, growth hormone disorders, and hormone replacement therapy. The company actively engages in strategic collaborations, notably including an agreement with Gilead Sciences, Inc. Furthermore, Novo Nordisk A/S is engaged in a research partnership with Lumen Bioscience, Inc., aiming to explore innovative methods for administering oral biologics for the management of cardiometabolic diseases. Established in 1923, the company's main corporate offices are located in Bagsvaerd, Denmark.

Stock Peers

BMYMP

-22-2.97%

Bristol-Myers Squibb Company PFD CONV 2$720.00 RHHBF

Roche Holding AG$303.00 RHHVF

4.25+1.57%

Roche Holding AG$275.25 AZNCF

AstraZeneca PLC$161.00 SNYNF

Sanofi$98.26 DSNKY

-0.42-1.17%

Daiichi Sankyo Company, Limited$35.52 DSKYF

-1.54-4.17%

Daiichi Sankyo Company, Limited$35.35 RHHBY

0.5+1.47%

Roche Holding AG$34.53 ORINY

Orion Oyj$21.35 GLAXF

-0.31-1.49%

GSK plc$20.50

Company Overview

Novo Nordisk A/S (OTC:NONOF) closed at $44.14 USD, losing -$0.33 (-0.73%) from the previous close of $44.47. The stock is currently mid-range between its 52-week high and low $34.00 and $64.75. With a market capitalization of about $196.02 billion, Novo Nordisk A/S is classified as a large-cap and shows lower-than-market volatility (beta ~0.35). Key stats such as the average daily volume over the past year has been around 66.06 thousand shares, volume is running light vs its 52-week average. Headquartered in Bagsvaerd, CR, Novo Nordisk A/S operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Maziar Mike Doustdar, the company employs approximately 68,794 people and listed since May 07, 2010. Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products.

Technical Performance

Average 10-day trading volume of 10.97 thousand shares is below the 3-month average of 64.39 thousand, indicating normal recent market interest.

Valuation Metrics

Novo Nordisk A/S trades at a P/E ratio of 10.96, slightly below the S&P 500 average, with a price-to-sales ratio of 3.87 and a price-to-book ratio of 5.75 trading at moderately above to book value. The P/FCF stands at 16.75, also above market averages.

Dividend & Fair Value

Novo Nordisk A/S last paid a dividend of 1.8 per share, this equals a trailing yield of roughly 7.24%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $74.90. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Novo Nordisk A/S earnings surprise history is a mixed track record. The quarter that ended August 05, 2026, missed forecasts by 22.82%. The prior quarter beat by 10.27%. Over the last six quarters, Apple has recorded several small beats. These include 0.53% in August 06, 2025.

Financial & Profitability Overview

Over the trailing twelve months, Novo Nordisk A/S generated $232.26B in revenue, or $51.67 per share. Gross margin was 84.60%, operating margin 44.16%, and net profit margin 36.03%. Returns are exceptional, with ROA at 26.61% and ROE at 78.53%.
On valuation metrics, Novo Nordisk A/S trades at a P/E of 10.96, P/S of 3.87 and P/B of 5.75. Liquidity is tight, with a current ratio of 0.87 and quick ratio of 0.66. Operationally, the company’s inventory turnover is 1.24 and cash conversion cycle is -471.95 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.63, supported by a cash flow-to-debt ratio of 0.95.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Novo Nordisk A/S posted revenue of $232.26B, down slightly from $176.95B in the prior quarter. Gross profit was $196.50B (margin 84.60%). Operating income was $102.57B (margin 44.2%). Net income was$83.68B (EPS $18.67).
The company ended the quarter with $30.23B in cash and short-term investments, a total debt of $27.01B, and net debt of $12.61B. Total assets were $314.49B, with equity of $106.56B. Financials further reflected robust performance, with operating cash flow of $108.91B, free cash flow of $70.01B, and capital expenditures of - $38.90B.

Price Forecast & Outlook

Our AI price prediction model suggests that Novo Nordisk A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Novo Nordisk A/S trading at a premium to the broader market with a P/E of 10.96.

Frequently Asked Questions

What is the current Novo Nordisk A/S (NONOF) stock price?

Novo Nordisk A/S (OTC: NONOF) stock price is $44.14 in the last trading session. During the trading session, NONOF stock reached the peak price of $44.74 while $43.97 was the lowest point it dropped to. The percentage change in NONOF stock occurred in the recent session was -0.73% while the dollar amount for the price change in NONOF stock was - $0.33.

NONOF's industry and sector of operation?

The OTC listed NONOF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Novo Nordisk A/S designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NONOF?

Ms. Camilla Sylvest
Executive Vice President of Commercial Strategy & Corporation Affairs and Member of the Management Board
Mr. Maziar Mike Doustdar
Executive Vice President of International Operations & Member of the Management Board
Mr. Henrik Ehlers Wulff
Executive Vice President of Product Supply, Quality & IT and Member of the Management Board
Dr. Marcus Schindler Ph.D.
EVice President of Research & Early Devel., Chief Scientific Officer & Member of the Management Board
Mr. Douglas J. Langa
Executive Vice President of North America Operations & Member of Management Board
Mr. Karsten Munk Knudsen
Executive Vice President, Chief Financial Officer & Member of the Management Board
Mr. Ludovic Helfgott
Executive Vice President, Head of Rare Disease & Member of Management Board
Mr. Lars Fruergaard Jorgensen
Pres, Chief Executive Officer & Member of Management Board
Dr. Martin Holst Lange
Executive Vice President of Devel. & Member of the Management Board
Ms. Tania Sabroe
Executive Vice President of Global People & Organisation and Member of Management Board

How NONOF did perform over past 52-week?

NONOF's closing price is 94.04% higher than its 52-week low of $34.00 where as its distance from 52-week high of $64.75 is -2.39%.

How many employees does NONOF have?

Number of NONOF employees currently stands at 68,794.

Link for NONOF official website?

Official Website of NONOF is: https://www.novonordisk.com

How do I contact NONOF?

NONOF could be contacted at phone 454 444 8888 and can also be accessed through its website. NONOF operates from Novo Alle 1, Bagsvaerd, CR 2880, Denmark.

How many shares of NONOF are traded daily?

NONOF stock volume for the day was 241 shares. The average number of NONOF shares traded daily for last 3 months was 66.06K.

What is the market cap of NONOF currently?

The market value of NONOF currently stands at $196.02B with its latest stock price at $44.14 and 4.44B of its shares outstanding.

Employees	68794
Beta	0.35
Sales or Revenue	$232.26B
5Y Sales Change%	1.242%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

NONOF Company Profile and Key Details

Novo Nordisk A/S

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Company Overview

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook

Valuation Metrics